We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

New Formulation Boosts Effectiveness of Prostate Cancer Drug by 40% in Preclinical Study

News   Jun 22, 2020 | Original story from the University of South Australia

 
New Formulation Boosts Effectiveness of Prostate Cancer Drug by 40% in Preclinical Study

A novel formulation of the prostate cancer drug abiraterone acetate - currently marketed as Zytiga - will dramatically improve the quality of life for people suffering from prostate cancer. Credit: Hayley Schultz/UniSA

 
 
Advertisement
 

RELATED ARTICLES

How Bacteria in Cystic Fibrosis Patients Overcome Treatments

News

Researchers have discovered a slimy strategy used by bacteria to defeat antibiotics and other drugs used to combat infections afflicting people with cystic fibrosis.

READ MORE

New Type of Bone Cell Identified

News

The discovery of a new type of bone cell may uncover therapeutic targets for a range of skeletal diseases.

READ MORE

Janssen COVID-19 Vaccine Issued Emergency Use Authorization by the FDA

News

The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) to the Janssen Pharmaceuticals Companies of Johnson & Johnson for its single-shot COVID-19 vaccine, called Ad.26.COV2S or JNJ-78436725.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE